Navigation Links
Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
Date:6/27/2012

NEW YORK, June 27, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential wrongdoing at Pain Therapeutics Inc.  ("PTIE" or the "Company") (Nasdaq: PTIE).  The investigation focuses on whether certain executive officers and directors of PTIE breached their fiduciary duties by releasing false and misleading statements regarding its lead drug, REMOXY, and the likelihood that REMOXY would be approved by the Food and Drug Administration ("FDA").  REMOXY is marketed as a strong painkiller with a unique formulation designed to reduce potential risks of unintended use.

(Logo:  http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

Specifically, the investigation concerns possible breaches of fiduciary duties by the Company's executive officers and directors for failing to disclose that REMOXY was not approvable by the FDA due to chemistry, manufacturing and control deficiencies that caused inconsistent results during laboratory tests of REMOXY.  On June 24, 2011, the Company announced that a Complete Response Letter was received from the FDA rejecting the Company's New Drug Application ("NDA") for REMOXY.  To date, a new NDA for REMOXY has not been submitted to the FDA nor has the Company meaningfully updated investors regarding any plan to do so.

Request more information now by clicking here: www.faruqilaw.com/PTIE. There is no cost or obligation to you.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action and derivative litigation.  The firm is focused on providing exemplary legal services in the areas of securities, shareholder, antitrust and consumer litigation, through all phases of litigation.  The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients.

If you hold PTIE shares and you would like to discuss your legal rights, visit www.faruqilaw.com/PTIE.  You can also contact us by calling Beth Keller toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to bkeller@faruqilaw.com.

Contact:

Faruqi & Faruqi, LLP
Beth A. Keller, Esq.
369 Lexington Avenue, 10th Floor
New York, NY 10017
Telephone: (877) 247-4292 or (212) 983-9330
E-mail: bkeller@faruqilaw.com

(Nasdaq: PTIE)

Attorney Advertising. (C) 2012 Faruqi & Faruqi, LLP.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.


'/>"/>
SOURCE Faruqi & Faruqi, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
2. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Sterne, Kessler, Goldstein & Fox Selected by 15 Year Old Winner of Intel International Science and Engineering Fair
5. Berg Pharma and the Parkinsons Institute ink R&D collaboration to drive disease understanding and accelerate therapeutic and diagnostic development in Parkinsons Disease
6. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
7. Morrison & Foersters Kate Murashige Wins Chambers Lifetime Achievement Award
8. Frost & Sullivan to Host Complimentary Web Conference: Concerns and Solutions for the Anaesthesia Equipment and Associated Peripherals Market
9. U.S. News & World Report and Pharmacy Times Announce "Top Recommended Health Products"
10. Electronic Medical Records Progress from an Enterprise-Centric Solution to a Customer-Specific Application, Finds Frost & Sullivan
11. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... named one of Michigan’s 2017 Best and Brightest in Wellness® by Best and ... Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. ...
Breaking Medicine News(10 mins):